Sep 29, 2026 · 1h 23m
ALS research confronts a disease with many faces
Ep 223 ALS: Unraveling the mystery
ALS remains devastating and biologically complex, while limited treatments and emerging therapies make better diagnosis and research models urgent.
- 1ALS damages upper and lower motor neurons, producing varied movement, muscle, and bulbar symptoms.
- 2Genetic risk, TDP-43 aggregates, and links to frontotemporal dementia suggest ALS comprises several related diseases.
- 3Current treatments offer limited benefit, but gene therapies, viral vectors, and microRNAs are expanding the research frontier.
Don't miss
Lou Gehrig’s extraordinary baseball career and the early signs of illness that ended it become the episode’s most vivid historical passage.
The brief
A firsthand family account opens the episode by showing ALS as more than a neurological diagnosis: it is a prolonged crisis for patients and caregivers.
The hosts explain how degeneration in upper and lower motor neurons produces weakness, spasms, atrophy, fasciculations, hyperreflexia, and bulbar symptoms.
ALS appears biologically diverse, with familial and sporadic forms, TDP-43 aggregates, genetic risk, and a close relationship to frontotemporal dementia.
Current treatments such as riluzole and edaravone have limited effects, while caregiving remains demanding and research models still struggle to capture the disease.
Lou Gehrig’s rise, public image, and career-ending illness give the disease its most recognizable history, before the episode turns to gene therapies and other emerging approaches.
The episode ends with a tension at the center of ALS research: the disease remains poorly understood, but persistence is producing increasingly precise therapeutic strategies.
Featuring
Lou Gehrig
Jean-Martin Charcot
frontotemporal dementiaBooks & mentions
Listen to the full episode and explore every guest, topic, and moment on PodLume.